← Back to Search

Radiation Therapy

Palliative Radiotherapy for Cancer

Phase 2

Recruiting

Led By Amy Xu, MD, PhD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status 0-2

Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 month

Awards & highlights

Study Summary

This trial will test a lower dose of radiation to see if it is still effective against cancer that has spread and has an ATM mutation.

Who is the study for?

This trial is for adults over 18 with a life expectancy of at least 6 months who have cancer that has spread and shows a specific genetic change (ATM mutation). They should be able to undergo reduced-dose radiation therapy, not previously treated in the same area, and must agree to use effective contraception.Check my eligibility

What is being tested?

The study is examining if lower doses of radiation can still effectively treat metastatic tumors with an ATM mutation. It aims to determine the minimum effective dose of palliative radiotherapy for these patients.See study design

What are the potential side effects?

While not specified here, common side effects from reduced-dose radiation may include skin irritation, fatigue, mild swelling or pain around the treatment area. The severity often depends on individual patient factors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself and perform daily activities.

Select...

My cancer has spread, and I am referred for symptom relief radiation.

Select...

I am 18 years old or older.

Select...

I have a genetic mutation in the ATM gene.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Treatment failure rate of irradiated lesion

Trial Design

1Treatment groups

Experimental Treatment

Group I: radiationExperimental Treatment1 Intervention

Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Palliative radiotherapy

2015

Completed Phase 2

~30

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,869 Total Patients Enrolled

Amy Xu, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

2 Previous Clinical Trials

185 Total Patients Enrolled

Media Library

Palliative radiotherapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05010031 — Phase 2

Cancer Clinical Trial 2023: Palliative radiotherapy Highlights & Side Effects. Trial Name: NCT05010031 — Phase 2

Palliative radiotherapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05010031 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what degree is Palliative radiotherapy innocuous for patients?

"There is some evidence of Palliative radiotherapy's safety, thus it was assigned a rating of 2. It should be noted that there are no clinical studies to corroborate effectiveness yet."

Answered by AI

To which locations is this research being conducted?

"Seven locations are hosting patient recruitment for this trial: Harrison, Middletown and New york amongst others. It is advisable that participants choose the location nearest them to minimize their commute when taking part in the experiment."

Answered by AI

Are participants currently being invited to partake in this clinical experiment?

"Affirmative. Clinicaltrials.gov provides evidence that this clinical study is currently recruiting participants, having first been posted on August 11th 2021 and last updated September 23rd 2022."

Answered by AI

What is the scope of patients participating in this research?

"True, the clinical trial is currently open for enrollment. The study was originally published on August 11th 2021 and most recently updated on September 23rd 2022. A total of 58 individuals are needed to participate across 7 different medical sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

2021. "A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05010031.